{
  "company": {
    "name": "Attune Pharmaceuticals",
    "website": "https://attunepharma.com/",
    "record": "https://startuphistory.org/c/attunepharma.com"
  },
  "status": null,
  "history_since": "2017-08-10T14:02:06.000Z",
  "baseline": {
    "snapshot_id": "f9510ebc8cba5f3f83f85f62828f8afc954891f22416bed33b49c48f939b676c",
    "observed_at": "2017-08-10T14:02:06.000Z",
    "headline": null,
    "description": "Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel oral once-daily small-molecule therapeutics for the treatment of rare diseases.",
    "evidence": "https://web.archive.org/web/20170810140206/http://attunepharma.com:80/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [],
  "changes": [
    {
      "n": 1,
      "id": "page-52add73cb3df1c76a29246ec50e8e71f3489c49a71c024a99d507fec5a4ad8af:042ea07b42c5de95d3ec11437d59d764493b5f489e7a42b2ceb737d5c4197a75:funding:d4456924708f8a60",
      "before_evidence": "https://web.archive.org/web/20180807224344/http://attunepharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More >”.",
      "between": {
        "from": "2018-08-07T22:43:44.000Z",
        "to": "2019-07-07T05:28:45.000Z"
      },
      "evidence": "https://web.archive.org/web/20190707052845/http://attunepharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    },
    {
      "n": 2,
      "id": "page-042ea07b42c5de95d3ec11437d59d764493b5f489e7a42b2ceb737d5c4197a75:4687016629990b0cbfba7a23f909961e56c9c625085a27defe60292754fdd33a:funding:d4456924708f8a60",
      "before_evidence": "https://web.archive.org/web/20190707052845/http://attunepharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More >”.",
      "between": {
        "from": "2019-07-07T05:28:45.000Z",
        "to": "2021-11-26T15:18:10.000Z"
      },
      "evidence": "https://web.archive.org/web/20211126151810/http://attunepharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    },
    {
      "n": 3,
      "id": "page-fdde973a1dda61f7fd508478cc42235a78ab5aa49551f53707c9e7906b0c483a:16ef75806347f66c234a1500f3f57790ece32d2b5fcdda7e71ffc9a55c250228:funding:d4456924708f8a60",
      "before_evidence": "https://web.archive.org/web/20240422032550/https://attunepharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “Media January 23, 2019 Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE Read More >”.",
      "between": {
        "from": "2024-04-22T03:25:50.000Z",
        "to": "2024-07-18T05:16:42.000Z"
      },
      "evidence": "https://web.archive.org/web/20240718051642/http://attunepharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    }
  ],
  "update": {
    "headline": "Attune Pharmaceuticals highlights Series B financing",
    "summary": "Attune Pharmaceuticals’ homepage features an announcement of $23M Series B financing to advance ATN-249 for the treatment of HAE across multiple observed periods.",
    "points": [
      {
        "text": "Between August 2018 and July 2019, Attune Pharmaceuticals’ homepage announced “Attune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAE”.",
        "kind": "fact",
        "changes": [
          1
        ]
      },
      {
        "text": "Between July 2019 and November 2021, the company’s homepage showed the same $23M Series B financing announcement for ATN-249 for the treatment of HAE.",
        "kind": "fact",
        "changes": [
          2
        ]
      },
      {
        "text": "Between April 2024 and July 2024, the homepage displayed the $23M Series B financing announcement to advance ATN-249 for the treatment of HAE.",
        "kind": "fact",
        "changes": [
          3
        ]
      },
      {
        "text": "The presence of the $23M Series B announcement across these periods may suggest this financing is an important part of how Attune Pharmaceuticals presents itself.",
        "kind": "interpretation",
        "changes": [
          1,
          2,
          3
        ]
      }
    ],
    "written_at": "2026-11-07T16:02:30.503Z",
    "basis": "ai_analysis",
    "model": "gpt-5.1-2025-11-13"
  },
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Attune Pharmaceuticals” company record, https://startuphistory.org/c/attunepharma.com"
}